5α-Androstanedione |
Catalog No.GF20672
One-Click Copy Product Info
|
5α-Androstanedione is an endogenous steroid hormone metabolite and a key intermediate.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 846-46-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
5α-Androstanedione is an endogenous steroid hormone metabolite and a key intermediate. 5α-Androstanedione promotes dihydrotestosterone synthesis as a product of 5α-reductase. 5α-Androstanedione can be used in research related to prostate diseases and steroid hormone drug synthesis[1-4].
In vitro, 5α-Androstanedione (100nM) stimulated VCaP prostate cancer cells for 24 hours, significantly inducing AR nuclear translocation and increasing PSA expression[5].
References:
[1] Sharifi N. Clinical implications of the 5α-androstanedione pathway for castration-resistant prostate cancer. Future Oncol. 2011 Nov;7(11):1239-41.
[2] Sharifi N. The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer. J Investig Med. 2012 Feb;60(2):504-7.
[3] Stanczyk FZ, Mandelbaum R, Baker M, et al. Quantitation of 5α-androstanedione in normal women and women with PCOS. J Steroid Biochem Mol Biol. 2023 Jul;231:106289.
[4] Hou Z, Yang T, Mei Z, et al. Tracing steroidogenesis in prostate biopsy samples to unveil prostate tissue androgen metabolism characteristics and potential clinical application. J Steroid Biochem Mol Biol. 2021 Jun;210:105859.
[5] Powell K, Semaan L, Conley-LaComb MK, et al. ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells. Clin Cancer Res. 2015 Jun 1;21(11):2569-79.
| Cell experiment [1]: | |
Cell lines | VCaP prostate cancer cells |
Preparation Method | VCaP cells were maintained in DMEM media with 10% fetal bovine serum and treated with 5α-Androstanedione (100nM) for 24 hours in 1% charcoal stripped serum phenol red-free DMEM media. |
Reaction Conditions | 100nM; 24h |
Applications | 5α-Androstanedione induced AR translocation into the nucleus and increased PSA expression in VCaP cells. 5α-Androstanedione treatment caused a strong correlation of AR with the nucleus (r=0.72) compared to vehicle control (r=0.38). 5α-Androstanedione was converted to DHT via AKR1C3 enzyme in VCaP cells. |
References: | |
| Cas No. | 846-46-8 | SDF | |
| Formula | C19H28O2 | M.Wt | 288.424 |
| Solubility | Storage | Store at RT | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4671 mL | 17.3356 mL | 34.6712 mL |
| 5 mM | 693.4 μL | 3.4671 mL | 6.9342 mL |
| 10 mM | 346.7 μL | 1.7336 mL | 3.4671 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)